Homework Help is Here – Start Your Trial Now!
Math
Statistics
Using the table below and the Agresti-Coull 95% confidence interval equation for proportions (page 193), calculate the upper and lower confidence intervals for the number of deaths due to Covid-19/SARS- CoV-2 in the placebo group; a death in this case is a success. Address the question, "Does the number of deaths due to Covid-19/SARS-CoV-2 in the placebo group differ from zero?" If the confidence interval contains zero, it is not statistically different from zero. Provide the following: 1) Null and alternative hypotheses. 2) The upper and lower confidence interval values and p-hat (estimated proportion of deaths). 3) Whether you reject or fail to reject the null hypothesis. Table S26. Death summary in Blinded Phase Placebo N=15162 16 (0.1) MRNA-1273 N=15184 16 (0.1) Total N-30346 32 (0.1) Number of Deaths Total, n (%) Cause of death, n Symptomatic Covid-19 Covid-19//SARS-CoV-2 Intra-abdominal perforation Stage 4 pancreatic cancer Complication of amyotrophic lateral sclerosis Myocardial infarction Cardiopulmonary arrest Unknown death (details unknown, pending autopsy, unknown origin/cause). Severe systemic inflammatory syndrome in the setting of CLL Committed suicide Seizure End stage congestive heart failure Cardiac arrest Provisional diagnosis, sudden fatal event, likely myocardial infarction Worsening metastatic hepatocellular carcinoma Right lower lobe pulmonary nodule concerning for primary lung malignancy GI bleed and multisystem organ failure and acute hypoxic respiratory failure Head trauma Death suspected due to coronary artery disease, probably to complications of diabetes mellitus Percentages based on participants in the safety set. tParticipant with a medical history of liver disease and human immunodeficiency virus, had a death attributed to Covid-19 that occurred 119 days post-dose 1; however, did not receive a second dose and was not included in the analysis of the secondary endpoint for prevention of Covid-19 death as only deaths due to Covid-19 14 days after 2nd dose were analyzed. Data-cutoff date March 26, 2021. 1. 1t 1 1 1 3 1 1 1 1 1

Using the table below and the Agresti-Coull 95% confidence interval equation for proportions (page 193), calculate the upper and lower confidence intervals for the number of deaths due to Covid-19/SARS- CoV-2 in the placebo group; a death in this case is a success. Address the question, "Does the number of deaths due to Covid-19/SARS-CoV-2 in the placebo group differ from zero?" If the confidence interval contains zero, it is not statistically different from zero. Provide the following: 1) Null and alternative hypotheses. 2) The upper and lower confidence interval values and p-hat (estimated proportion of deaths). 3) Whether you reject or fail to reject the null hypothesis. Table S26. Death summary in Blinded Phase Placebo N=15162 16 (0.1) MRNA-1273 N=15184 16 (0.1) Total N-30346 32 (0.1) Number of Deaths Total, n (%) Cause of death, n Symptomatic Covid-19 Covid-19//SARS-CoV-2 Intra-abdominal perforation Stage 4 pancreatic cancer Complication of amyotrophic lateral sclerosis Myocardial infarction Cardiopulmonary arrest Unknown death (details unknown, pending autopsy, unknown origin/cause). Severe systemic inflammatory syndrome in the setting of CLL Committed suicide Seizure End stage congestive heart failure Cardiac arrest Provisional diagnosis, sudden fatal event, likely myocardial infarction Worsening metastatic hepatocellular carcinoma Right lower lobe pulmonary nodule concerning for primary lung malignancy GI bleed and multisystem organ failure and acute hypoxic respiratory failure Head trauma Death suspected due to coronary artery disease, probably to complications of diabetes mellitus Percentages based on participants in the safety set. tParticipant with a medical history of liver disease and human immunodeficiency virus, had a death attributed to Covid-19 that occurred 119 days post-dose 1; however, did not receive a second dose and was not included in the analysis of the secondary endpoint for prevention of Covid-19 death as only deaths due to Covid-19 14 days after 2nd dose were analyzed. Data-cutoff date March 26, 2021. 1. 1t 1 1 1 3 1 1 1 1 1

MATLAB: An Introduction with Applications
MATLAB: An Introduction with Applications
6th Edition
ISBN:9781119256830
Author:Amos Gilat
Publisher:Amos Gilat
Chapter1: Starting With Matlab
Section: Chapter Questions
Problem 1P
See similar textbooks
icon
Related questions
Question
Find the upper and lower confidence interval values and p-hat using the Agresti-Coull 95% confidence interval equation
Using the table below and the Agresti-Coull 95% confidence interval equation for proportions (page 193), calculate the upper and lower confidence intervals for the number of deaths due to Covid-19/SARS- CoV-2 in the placebo group; a death in this case is a success. Address the question, "Does the number of deaths due to Covid-19/SARS-CoV-2 in the placebo group differ from zero?" If the confidence interval contains zero, it is not statistically different from zero. Provide the following: 1) Null and alternative hypotheses. 2) The upper and lower confidence interval values and p-hat (estimated proportion of deaths). 3) Whether you reject or fail to reject the null hypothesis. Table S26. Death summary in Blinded Phase Placebo N=15162 16 (0.1) MRNA-1273 N=15184 Total N=30346 32 (0.1) Number of Deaths Total, n (%) Cause of death, n Symptomatic Covid-19 Covid-19//SARS-CoV-2 Intra-abdominal perforation Stage 4 pancreatic cancer Complication of amyotrophic lateral sclerosis Myocardial infarction Cardiopulmonary arrest Unknown death (details unknown, pending autopsy, unknown origin/cause). Severe systemic inflammatory syndrome in the setting of CLL Committed suicide Seizure End stage congestive heart failure Cardiac arrest Provisional diagnosis, sudden fatal event, likely myocardial infarction Worsening metastatic hepatocellular carcinoma Right lower lobe pulmonary nodule concerning for primary lung malignancy GI bleed and multisystem organ failure and acute hypoxic respiratory failure Head trauma Death suspected due to coronary artery disease, probably to complications of diabetes mellitus Percentages based on participants in the safety set. tParticipant with a medical history of liver disease and human immunodeficiency virus, had a death attributed to Covid-19 that occurred 119 days post-dose 1; however, did not receive a second dose and was not included in the analysis of the secondary endpoint for prevention of Covid-19 death as only deaths due to Covid-19 14 days after 2nd dose were analyzed. Data-cutoff date March 26, 2021. 16 (0.1) 1 1 1t 1 1 4. 3 5 1. 1 1 1 1 1 1 1.
Transcribed Image Text:Using the table below and the Agresti-Coull 95% confidence interval equation for proportions (page 193), calculate the upper and lower confidence intervals for the number of deaths due to Covid-19/SARS- CoV-2 in the placebo group; a death in this case is a success. Address the question, "Does the number of deaths due to Covid-19/SARS-CoV-2 in the placebo group differ from zero?" If the confidence interval contains zero, it is not statistically different from zero. Provide the following: 1) Null and alternative hypotheses. 2) The upper and lower confidence interval values and p-hat (estimated proportion of deaths). 3) Whether you reject or fail to reject the null hypothesis. Table S26. Death summary in Blinded Phase Placebo N=15162 16 (0.1) MRNA-1273 N=15184 Total N=30346 32 (0.1) Number of Deaths Total, n (%) Cause of death, n Symptomatic Covid-19 Covid-19//SARS-CoV-2 Intra-abdominal perforation Stage 4 pancreatic cancer Complication of amyotrophic lateral sclerosis Myocardial infarction Cardiopulmonary arrest Unknown death (details unknown, pending autopsy, unknown origin/cause). Severe systemic inflammatory syndrome in the setting of CLL Committed suicide Seizure End stage congestive heart failure Cardiac arrest Provisional diagnosis, sudden fatal event, likely myocardial infarction Worsening metastatic hepatocellular carcinoma Right lower lobe pulmonary nodule concerning for primary lung malignancy GI bleed and multisystem organ failure and acute hypoxic respiratory failure Head trauma Death suspected due to coronary artery disease, probably to complications of diabetes mellitus Percentages based on participants in the safety set. tParticipant with a medical history of liver disease and human immunodeficiency virus, had a death attributed to Covid-19 that occurred 119 days post-dose 1; however, did not receive a second dose and was not included in the analysis of the secondary endpoint for prevention of Covid-19 death as only deaths due to Covid-19 14 days after 2nd dose were analyzed. Data-cutoff date March 26, 2021. 16 (0.1) 1 1 1t 1 1 4. 3 5 1. 1 1 1 1 1 1 1.
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 2 steps

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
MATLAB: An Introduction with Applications
MATLAB: An Introduction with Applications
Statistics
ISBN:
9781119256830
Author:
Amos Gilat
Publisher:
John Wiley & Sons Inc
Probability and Statistics for Engineering and th…
Probability and Statistics for Engineering and th…
Statistics
ISBN:
9781305251809
Author:
Jay L. Devore
Publisher:
Cengage Learning
Statistics for The Behavioral Sciences (MindTap C…
Statistics for The Behavioral Sciences (MindTap C…
Statistics
ISBN:
9781305504912
Author:
Frederick J Gravetter, Larry B. Wallnau
Publisher:
Cengage Learning
Elementary Statistics: Picturing the World (7th E…
Elementary Statistics: Picturing the World (7th E…
Statistics
ISBN:
9780134683416
Author:
Ron Larson, Betsy Farber
Publisher:
PEARSON
The Basic Practice of Statistics
The Basic Practice of Statistics
Statistics
ISBN:
9781319042578
Author:
David S. Moore, William I. Notz, Michael A. Fligner
Publisher:
W. H. Freeman
Introduction to the Practice of Statistics
Introduction to the Practice of Statistics
Statistics
ISBN:
9781319013387
Author:
David S. Moore, George P. McCabe, Bruce A. Craig
Publisher:
W. H. Freeman
SEE MORE TEXTBOOKS